Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -691.81% is 14% above its 1-year average of -806.32%, near the high end of its 1-year range (-2433.88%–36.62%).
14.20% above its 12-month average of -806.32%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -1500.45%.
NET PROFIT MARGIN
-691.81%
NET PROFIT MARGIN AVG TTM
-806.32%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
0.00%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+14.20%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
NRx Pharmaceuticals, Inc.
Market Cap
$125.34M
Net Profit Margin
-691.81%
TTM Avg
-806.32%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$126.43M
Net Profit Margin
-27235.71%
TTM Avg
-16253.49%
3Y Avg
-10565.36%
5Y Avg
-7911.44%
Market Cap
$122.26M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$121.75M
Net Profit Margin
-2258.89%
TTM Avg
-4695.34%
3Y Avg
-8719.58%
5Y Avg
-5863.11%
Market Cap
$121.95M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$121.23M
Net Profit Margin
-490.71%
TTM Avg
-538.75%
3Y Avg
-569.71%
5Y Avg
-1398.02%
Market Cap
$118.05M
Net Profit Margin
-586.74%
TTM Avg
-215.13%
3Y Avg
-125.58%
5Y Avg
-83.72%
Market Cap
$117.03M
Net Profit Margin
-1030.42%
TTM Avg
-1409.68%
3Y Avg
-958.30%
5Y Avg
-801.33%
Market Cap
$133.75M
Net Profit Margin
-90.61%
TTM Avg
-39.94%
3Y Avg
-42.38%
5Y Avg
-48.96%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NRx Pharmaceuticals, Inc. (NRXP) | $125.34M | -691.81% | -806.32% | 0.00% | 0.00% |
| Entera Bio Ltd. (ENTX)vs › | $126.43M | -27235.71% | -16253.49% | -10565.36% | -7911.44% |
| enGene Holdings Inc. (ENGN)vs › | $122.26M | 0.00% | 0.00% | 0.00% | 0.00% |
| Cibus, Inc. (CBUS)vs › | $121.75M | -2258.89% | -4695.34% | -8719.58% | -5863.11% |
| TuHURA Biosciences, Inc. (HURA)vs › | $121.95M | 0.00% | 0.00% | 0.00% | 0.00% |
| Seer, Inc. (SEER)vs › | $121.23M | -490.71% | -538.75% | -569.71% | -1398.02% |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.05M | -586.74% | -215.13% | -125.58% | -83.72% |
| Caribou Biosciences, Inc. (CRBU)vs › | $117.03M | -1030.42% | -1409.68% | -958.30% | -801.33% |
| Health Catalyst, Inc. (HCAT)vs › | $133.75M | -90.61% | -39.94% | -42.38% | -48.96% |
| Organigram Global Inc. (OGI)vs › | $133.34M | 27.54% | -18.99% | -63.93% | -73.34% |
Operating Margin
-1324.4%
Net Profit Margin
-691.8%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -1500.45% |
| 2026-03-31 | -133.90% |
| 2025-12-31 | 36.62% |
| 2025-09-30 | -2433.88% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |